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Highlights 
Heterologous expression-based system was used for phenotypic analysis of Vpr protein. 
GSH or ATP supplementation protected yeasts from Vpr-induced growth reduction 
Metabolites that stimulate GSH biosynthesis similarly protected from Vpr effect 
Vpr caused intracellular depletion of energy stores and subsequent oxidative damage 
Data showed that S. cerevisiae may be useful in screening for specific Vpr inhibitors 
Abstract 
The human immunodeficiency virus type 1 (HIV-1) encodes for accessory viral protein R (Vpr), 
which arrests the cell cycle of host cells at G2 and causes mitochondrial dysfunction and alterations 
in glycolysis. High-level expression of Vpr protein correlates with increased viral production and 
disease progression. Vpr causes structural and functional injury in many types of eukaryotic cells, 
whether or not they are permissive for viral replication; among them is the budding yeast 
Saccharomyces cerevisiae. We hypothesized that the dramatic Vpr-induced injuries in yeast could be 
prevented by strengthening their redox response capacity. We show that exogenous addition of 
glutathione (GSH) or its prodrug, N-acetylcysteine (NAC), protected budding yeasts from Vpr-
induced cytopathic effects. Moreover, addition of adenosine triphosphate (ATP) to growing cultures 
of Vpr-producing yeast returned cellular growth to control levels, whereas the addition 
dehydroascorbic acid (DHA) had only a minor protective effect. The diminished protein levels of 
Cox2p and Cox4p in wild type Vpr-producing yeasts together with the acute sensitivity of petite 
yeasts to Vpr activity may have been caused by low intracellular ATP levels. As a consequence of 
this energy deficit, eukaryotic cells would be unable to synthetize adequate supplies of GSH or to 
signal the mitochondrial retrograde response. Our findings strongly suggest that the cytopathogenic 
effect of Vpr protein in eukaryotic cells can be prevented by increasing intracellular antioxidant 
stores or, alternatively, supplying external ATP. Furthermore, these results support a potentially 
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1. Introduction 
Viral protein R (Vpr) is a 14 kDa accessory protein of human immunodeficiency virus type 1 (HIV-
1) encoded by vpr late gene (Cohen et al., 1990). Vpr protein can be found either inside or outside of 
host cells, localizing in the nucleus, cytoplasm and mitochondria, packed into virions or free in 
cerebrospinal fluids and plasma (Lu et al., 1993; Jacotot et al., 2000; Levy et al., 1994).  Although 
dispensable in some ex vivo infections, Vpr protein increases viral replication of T cells, is essential 
for HIV-1 infection of macrophages and determines disease progression (Dedera et al., 1989; Connor 
et al., 1995; Goh et al., 1998; Mologni et al., 2006).  
Newly synthesized Vpr causes pleiotropic effects in eukaryotic cells. Accordingly, Vpr prevents 
proliferation of infected cells by arresting them in G2 of the cell cycle, increases viral expression, 
provokes cell death of lymphoid target cells and induces a mitochondria-dependent apoptotic 
pathway (Goh et al., 1998; Muthumani et al., 2002; Rogel al., 1995). Extracellular and de novo 
synthesized Vpr protein has been used in a number of cellular models. Among them, the budding 
yeast Saccharomyces cerevisiae was demonstrated to be sensitive to Vpr activity (Zhao and Elder, 
2000). The fission yeast Schizosaccharomyces pombe reproduces Vpr-induced effects such as cell 
cycle G2 arrest, changes in cell shape and cell death (Zhao et al., 1998). Similarly, cell growth arrest, 
size alterations, transient respiratory deficiency and cell death by endogenously expressed or 
extracellular protein were Vpr-induced effects reported in S. cerevisiae (Macreadie et al., 1995; 
Macreadie et al., 1996; Macreadie et al., 1997; Jacotot et al., 2000). 
Vpr protein is an apoptogenic protein that induces mitochondrial membrane permeabilization via 
interaction with the adenine nucleotide translocator (ANT) in the inner mitochondrial membrane 
(Jacotot et al., 2001; Vieira et al., 2000). Studies using exogenous Vpr in microglial cells showed a 
reduction in the cellular levels of GSH and ATP and suggested an oxidative role for the extracellular 
form of Vpr protein, which is detected in serum and cerebrospinal fluid of HIV-infected patients 
(Ferrucci et al., 2012). Moreover, the oxidative status of host cells modulates the disease progress 




2000). While it is generally accepted that virus production increases in the presence of Vpr protein, 
the significance for Vpr-induced cytopathicity, in the context of the viral infection, is still debated 
(Ferrucci et al., 2013; Guenzel et al., 2014). Nevertheless, HIV-1-infected individuals display 
multiple symptoms of redox imbalance and Vpr is one of the viral proteins that can be involved in 
these phenomena (Antal and Pesti, 2006; Baruchel and Wainberg, 1992; Porter and Sutliff, 2012; 
Stromajer-Racz et al., 2010). Thus, HIV-1 infected cells endure elevations in reactive oxygen species 
(ROS), including superoxide and hydrogen peroxide, and show a decrease in their detoxification 
mechanisms. Reduction of total antioxidant capacity entails a significant decrease of GSH level in 
host cells (Nakamura et al., 2002) and recent studies have associated HIV-1 infection with GSH 
levels (Nguyen et al., 2014; Pang and Panee, 2014; Bhaskar et al., 2015). Notably, drugs that 
replenish intracellular GSH also counteract oxidative stress and inhibit HIV replication in models of 
acute and latent infection (Staal et al., 1992).  
In this study, we show that exogenous addition of ATP or GSH protected growing yeast from Vpr-
induced damage. The positive response of petite mutants to these treatments pointed to an 
impairment of an energetic pathway by Vpr. Moreover, the suppression of cell growth and resulting 
cell death induced by Vpr protein correlated with a downregulation of protein expression of the 
Cox4p subunit of cytochrome c oxidase. Therefore, we propose that Vpr expression leads to an ATP 
deficit in yeast that impairs the mitochondria retrograde response, a mechanism that would be 
expected to remedy the mitochondrial ATP deficit and consequent reduction in GSH stores. This 
Saccharomyces heterologous expression system might be a useful tool in searching for inhibitors 
targeted to Vpr protein. 
2. Materials and Methods 
2.1. Plasmid construction and microbial strains.  
E. coli DH5α strain (Sambrook and Rusell, 2001) was used for the construction of the  E.coli-yeast 
shuttle vector. The vpr gene sequence from the NL4-3 clone of HIV-1 (Adachi et al., 1986) was 
cloned into the SmaI and BamHI sites of pEMBLyex, a high copy number yeast expression vector 
carrying a galactose inducible and glucose repressible promoter (Cesareni and Murray, 1987). 
Exogenous gene expression is controlled by the CYCGAL1 promoter, which is tightly repressed by 
glucose and strongly induced by galactose. Two clones of S. cerevisiae W303-1B strain (Thomas and 
Rothstein, 1989) were used; a wild type clone and a petite mutant isolated after growth in the 
presence of ethidium bromide (Goldring et al., 1970), which was generously provided by M. 




characteristics of respiratory deficient mutants, such as slow growth and formation of small (petite) 
colonies in fermentable media (Ephrussi, 1949). 
2.2. Yeast media, transformation and induction.  
Yeast cells were grown at 30ºC, with orbital shaking at 300 rpm, in standard YNB glucose medium 
supplemented with 20 mg/l L-tryptophan, 40 mg/l adenine and 20 mg/l L-histidine. A standard 
lithium acetate protocol was used for production of competent yeast and transformation (Burke et al., 
2000). Transformants of the W303-1B strain (carrying pEMBLyex or pEMBLyex-vpr plasmids) 
were maintained in selective medium (containing 20 mg/l L-leucine). For vpr expression, yeast cells 
were cultured in YNB medium containing 2% galactose plus required supplements (inducing 
medium). The pH of media was adjusted with Trizma base. When required, solid medium was 
prepared by the addition of 1.5 % purified agar (Difco) to the broth. 
2.3. Assay conditions. 
All experiments were repeated at least three times using at least three cultures derived from 
independent colonies, with consistent results. Growth curves represent average data from three 
experiments. Before initiation of experiments, cells were grown in pH 7-adjusted non-inducing 
medium to the exponential phase. Following a washing step in MilliQ water, cells were diluted in 
fresh inducing medium and cell density was adjusted. Cell growth was estimated by measuring 
optical density at 600 nm (OD600) in a spectrophotometer (Genesys 10 VIS Thermo Scientific). 
Culturing was carried out at 30 ºC, with shaking at 300 rpm. Liquid cultures were initiated with 
exponentially growing cells diluted in inducing medium to an OD600 of 0.01 (corresponding to 2 x 
10
5
 cells/ml) or 0.1 (petite mutants). In growth kinetic assays, samples were collected after 24 h of 
incubation (t= 0 h) and OD600 was determined. Agar plate assays were performed with exponentially 
growing cells. After a washing step, cultures were diluted with fresh medium to an OD600 of 0.2 
(glucose) or 0.4 (galactose). Drop tests were carried out by spotting 5 µl of serial dilutions of the cell 
suspension onto agar plates. Drop tests used the same (non-inducing or inducing) pH- adjusted 
medium for dilutions and also to prepare agar plates. Plates were incubated for the indicated time at 
30 ºC and then scanned. 
2.4. Protein extraction and western blotting.  
Exponentially growing cells were diluted in YNB (2 % galactose) to an OD600 of 0.005. Samples (1 




cells were pelleted and suspended in 1 ml lysis buffer (0.2 M NaOH, 0.1 M β-mercaptoethanol and 
0.1 mM PMSF). After 5 min on ice, 2 µl of 100 % TCA was added and cell lysates were incubated at 
65 ºC for 5 min followed by incubation at 4 ºC for 5 min. The non-soluble fraction was collected by 
centrifugation and washed with cold (-20 ºC) acetone (Merck). The pellet was dried in a Speed-vac 
concentrator (Savant) and the extract was suspended in 100 µl sample buffer (0.16 M Tris-HCl pH 
6.8, 13.3 % glycerol (Merck), 2 % SDS, 1.5 % DTT and 0.033 % bromophenol blue). Lastly, 
samples were briefly sonicated and heated to 100 ºC for 5 min. Total protein content of each extract 
was measured using the Protein Assay Kit from Bio-Rad and concentrations were normalized to 
1mg/ml protein prior to loading onto SDS/20 % polyacrylamide gels. Proteins were transferred to 
nitrocellulose membranes by wet blotting. Protein transfer efficiency was monitored by Ponceau S 
staining. Membranes were subsequently cut into strips with the aid of molecular weight marker 
bands. Membranes were quickly destained in distilled water and blocked before addition of primary 
and secondary antibodies (Gonzalez and Carrasco, 2001). Labelled proteins were detected using 
ECL
TM
 Western Blotting Detection Reagents (Amersham). Membrane striping was carried out in a 
buffer containing 100 mM 2-Mercaptoetanol, 2 % SDS and 62.5 mM TrisHCl (pH 7) at 50 ºC for 30 
min. Membranes were subsequently reprobed. 
2.5. Antibodies.   
The Vpr monoclonal antibody was kindly provided by Dr. J. Koop (Provided by the EU Program 
EVA Centre for AIDS Reagents, NIBSC, UK. AVIP Contract Number LSHP-CT-2004-503487). 
The monoclonal antibodies, anti-yeast 3- phosphoglycerate kinase (PGK), anti-yeast mitochondrial 
porin (Por1), anti-yeast COX complex IV subunit II (Cox2p) anti-yeast COX complex IV subunit IV 
(Cox4p) and anti-yeast H+-ATPase 60 kDa subunit were purchased from Mitosciences. A primary 
monoclonal antibody to GAPDH and peroxidase-conjugated goat secondary antibodies (anti-rabbit 
or anti mouse) were purchased from Pierce.  
2.6. Transmission electron microscopy:  
Wild-type yeasts were cultured in induction medium and 48 h later cells were collected. Cells were 
fixed (5 min) in glutaraldehyde in 0.1 M cacodylate buffer, added as a 2x stock to the culture. Cells 
were collected by centrifugation and resuspended at 1 OD600/ml in fresh 1x fixative to complete 
fixation while gently rotating at room temperature (15 min). After potassium permanganate staining, 
samples were dehydrated and embedded in epoxy resin. Thin sections were prepared and mounted on 





3.1. Heterologous expression of HIV-1 Vpr protein causes cell death in Saccharomyces cerevisiae 
We used the same S. cerevisiae-based expression system with which we previously characterized the 
impairment of potassium transport by the HIV-1 Vpu viroporin (Gonzalez, 2015; Herrero et al., 
2013). An advantage of this system is its tight control of protein expression for extremely toxic  
 
Figure 1. Analysis of Vpr-induced effects in Saccharomyces cultures. Exponentially growing yeast transformed with 
control or vpr-plasmids, were suspended in defined synthetic medium to 0.5 OD600 and a series of 10-fold dilutions were 
prepared. Upper panel: Effect on culture growth. Direct drop test plating serial dilutions onto agar-YNB medium 
supplemented with glucose or galactose. Plates were incubated for 2 days and were then digitally scanned. Lower panel: 
Effect on cell survival. Control (pEMBLyex ) and Vpr (pEMBLyexvpr) cultures were diluted to 0.01 OD600 in inducing 
medium and incubated for the indicated periods before plating on rich medium supplemented with glucose. pEMBLyex -
yeasts (white) and pEMBLyexvpr -yeasts (black). 
 
proteins such as HIV-1 Vpr, and transformed cells achieve high-level production of the viral protein. 
Plating of transformed pEMBLyex-yeast and pEMBLyexvpr-yeast in induction medium resulted in 
growth differences between the two cultures. Growth achieved by control yeast was 3-log greater 
than Vpr-expressing yeast (Fig. 1 upper panel). After adaptation to the induction medium for 24 h, 
the control culture grew over the next two days and increased by 3-log the number of colony forming 
units (CFU) while the Vpr-expressing culture completely failed to proliferate (Fig. 1 lower panel). 
Furthermore, culture of transformed yeasts in induction medium led to cell death of Vpr-expressing 
cells since the number of colony forming units CFU in rich medium was reduced over time. These 
results suggest that, in addition to inhibiting cell growth, the cytotoxic effect of Vpr protein causes 




3.2. Protection from Vpr-induced growth arrest by antioxidant metabolites 
Previous studies reported that extracellular Vpr protein impairs astrocytic levels of intracellular GSH 
and ATP. We tested for protection from Vpr-induced cell damage by exogenous exposure of 
Saccharomyces to GSH or other metabolites related with GSH metabolism, including the GSH 
prodrug N-acetylcysteine (NAC), adenosine triphosphate (ATP) and the oxidized form of the 
antioxidant ascorbic acid, dehydroascorbic acid (DHA). Dose response analysis revealed that yeasts 
were protected from Vpr-induced growth reduction by GSH (Fig. 2). Compared with untreated cells, 
addition of GSH to levels just below the normal intracellular concentration of 10 mM (Penninckx, 
2002) protected against Vpr-induced inhibition of growth almost completely (Fig. 2). Addition of 10 
mM NAC also protected almost entirely against Vpr, although a higher concentration (15 mM) was 
cytostatic to the cultures. Addition of ATP offered poorer protection than GSH and NAC. The 
greatest protection was observed with 10 mM ATP, twice the physiological concentration. In 
contrast, the antioxidant DHA offered only minor protection from Vpr-induced growth arrest. 
Collectively, these results suggested that Vpr protein reduces intracellular ATP and GSH levels. 
 
Figure 2. Comparison of the dose responses of cultures to metabolites involved in the antioxidant defense. 
Transformed yeasts were treated with the indicated concentration of each compound from the initiation of galactose 
induction. Viability of each culture was analyzed after 2 days of treatment by counting the number of CFU obtained in 
rich medium. pEMBLyex yeasts (white) and pEMBLyexvpr -yeasts (black). UT: untreated cultures. 
 
To question whether Vpr affected mitochondria, we used western blotting to analyze distinct 
mitochondrial compartments in Vpr-treated cells with or without co-treatment with ATP, GSH, NAC 
or DHA. Mitochondrial markers used for this analysis were: mitochondrial protein localized in the 
outer membrane (OM, mitochondrial porin, Por1), inner membrane (IM, cytochrome c oxidase 




protein (PGK), a multi-localized protein (GAPDH), and Vpr protein. Striking differences were found 
between untreated Vpr cultures and Vpr cultures that were treated with ATP, GSH or NAC (Fig. 3). 
The relative levels of Cox2 and Cox4 proteins to the housekeeping proteins PGK and GAPDH were 
markedly different in treated than in untreated cultures, and levels of both mitochondrial IM proteins 
were clearly decreased in untreated Vpr-induced 
 
Figure 3. Western blot analysis of Vpr-induced changes in protein levels of endogenous proteins. Control 
(pEMBLyex ) and Vpr (pEMBLyexvpr) cells were incubated in inducing medium supplemented or not (UT) with 5mM 
ATP, 10 mM GSH or 10 mM NAC as indicated. Cultures were collected during early exponential growth and cellular 
extracts were prepared. Equal concentrations (1mg/ml in PBS) were loaded on SDS-PAGE gels. All samples were 
analyzed on the same blot. Panel A: Immunodetection of the proteins. Resolution of each protein band is indicated in 
brackets. H
+
-ATPase (60 kDa); PGK (45 kDa); GAPDH (38 kDa); Cox2p (35 kDa); Por1 (30 kDa); Cox4 (14 kDa); Vpr 
(14 kDa). The major band visualized after Ponceau S staining and expression of housekeeping genes PGK and GADPH 
help to compare   each sample load and relative protein levels. Panel B: Variations in protein contents by medium 
supplements. Digitalized protein bands were quantified using PCBAS software and obtained values were normalized 
with corresponding Ponceau S stain values. Protein levels of treated cultures relative to untreated cultures are represented 
as follows: ATP (white), GSH (grey), NAC (black). 
 
cultures. In contrast, similar differences were found between treated and untreated cultures in the 
level of the OM-localized mitochondrial protein, Por1, and glycolytic enzymes GADPH and PGK. It 
is noteworthy that levels of Cox2p, Cox4p and H
+
ATPase were decreased despite the higher amounts 
loaded onto the gel as shown by Ponceau S staining (Fig. 3). The finding that the cytochrome c 
oxidase subunits 2 and 4 and vacuolar ATPase proteins were more sensitive to Vpr than Por1 pointed 
to a disturbed cytochrome c oxidase (COX) and V-ATPase assembly. 
 




The above experiments were carried out in minimal synthetic medium, which ensured that 
exogenous GSH was not present unless specified. To guarantee that GSH was available when Vpr 
synthesis initiated, yeast cultures were pre-incubated with exogenous GSH or NAC prior to culture 
in galactose medium. We observed that cells were not protected against Vpr-induced damage by pre-
loading with GSH or NAC (data not shown). Thus, protection against Vpr-induced cytopathic effects 
appeared to require the presence of intracellular glutathione simultaneously with Vpr protein. 
We next examined the ultrastructure of yeast cells after galactose-induced expression of Vpr using 
transmission electron microscopy (TEM). A dramatic destruction of cell membrane structures could 
be observed in Vpr-cells, including the formation of aberrant vacuoles with membrane-bound 
vesicles, an unusual accumulation of intermediate endocytic profiles, deep indentations of the 
 
Figure 4. Ultrastructural analysis of Vpr-expressing cells. Representative transmission electron micrographs of 
ultrathin sectioned control (pEMBLyex ) and Vpr (pEMBLyex-vpr) cells. Yeast cultures growing in inducing medium 
with/without 10 mM GSH were collected after 48 h of incubation. Samples were processed and stained with potassium 
permanganate to highlight membrane structures as described in the materials and methods section. Representative single 
cells of each sample were photographed. 
 
vacuolar boundary membrane, autophagic bodies sequestered within, and cytoplasmic content 
engulfed by the vacuole (Fig. 4). Strikingly, the addition of GSH to the medium protected yeast from 
Vpr-induced morphological changes and the viral protein did not affect organelle membrane 
structures. 
Glutathione can exist under two forms: the reduced form of glutathione (GSH) has antioxidant 
capacity by acting as a free radical scavenger, becoming oxidized in the process; the oxidized form 
of glutathione (GSSG) can be recycled back to GSH by the action of glutathione reductase, using 




buffering capacity of cells, with optimal values ranging from 30-100:1. To examine whether the 
reducing capacity of glutathione was necessary for its protective effects on Vpr, we independently 
treated yeast cultures with oxidized and reduced forms of glutathione and compared their  
 
Figure 5. Protective capacity of the two redox forms of glutathione against Vpr-induced cytopathogenicity. Control 
(pEMBLyex ) and Vpr (pEMBLyex-vpr) yeast were incubated in inducing medium. Cultures were untreated (white) or 
treated with 10 mM GSSG (grey) or 10 mM GSH (black) during the culture. At the indicated time after induction, 
aliquots were removed from cultures and the OD600 was measured. The results are representative of three experiments. 
 
growth kinetics after induction of Vpr expression. At early stages of growth, less than 24 h after 
induction of vpr expression, a slight increase in Vpr-culture growth was observed in cultures 
supplemented with the reduced form of glutathione (Fig. 5). As incubation times increased, both 
reduced and oxidized forms caused increased culture growth relative to control cultures; however, 
GSH stimulated the growth of Vpr-induced cells 3-fold compared with GSSG-treated cells (Fig. 5), 
suggesting that the reducing power of GSH was used by cells as a defense against the cytopathic 
effects induced by Vpr.  
3.4. Respiratory deficient yeasts are vulnerable to Vpr-induced damage  
We questioned whether respiratory-deficient yeast would also be damaged by Vpr protein. To 
address this, we used a petite mutant that is incapable of using non-fermentable carbon sources such 
as glycerol. Thus, petite Saccharomyces was transformed with control or vpr-containing constructs 





Figure 6. Vpr activity in respiratory-deficient mutants. Panel A: Growth kinetics in non-inducing and inducing 
media. Exponentially growing yeasts were diluted in synthetic medium containing glucose or galactose (0 days). OD600 
was measured at the indicated periods of incubation. Panel B: Vpr effect on respiratory-deficient yeast treated with 
metabolites of antioxidant defense: Transformed yeasts (carrying pEMBLyex or pEMBLyex-vpr plasmids) were 
untreated (UT) or treated with the indicated compounds in inducing medium for 8 days. Cell density reached by each 
treated culture was measured by determining the OD600 and was represented as the fold change relative to untreated 
controls. Graph shows mean values from duplicate cultures. Error bars show standard deviation. Control yeast (white); 
Vpr yeast (black). Western blot analysis shows the immunodetection of indicated proteins after further incubation, for 
one day, of Vpr cells. Numbers in the table represent, in arbitrary units, the quantification of each protein band. 
 
galactose-supplemented synthetic medium exhibited a long latency phase before initiating 
exponential growth (Fig. 6A). Indeed, galactose-grown control cells took 4-times longer to reach the 
equivalent growth level as glucose-grown control cells. Surprisingly, the growth of Vpr-induced cells 
was completely arrested by culture in inducing medium (Fig. 6A). These results imply that Vpr 
might not interfere directly with respiration since these cells are adapted to survive using non-
respiratory metabolism. We therefore decided to examine the effects of exogenous glutathione in the 
sensitivity of petite cells to Vpr. Treatment of this mutant with GSH, its prodrug NAC, ATP or DHA 
induced an early stimulation of growth in control cultures (Fig. 6B). The presence of Vpr protein was 
confirmed in all Vpr-cultures (Fig. 6B). After 9 days of treatment, control yeasts reached the 
maximum growth levels (data not shown). Because of this, the comparative growth levels were 
assessed while cells are still growing. The growth stimulation of Vpr-induced cultures by all 




differential stimulation of growth was less marked with ATP treatment (Fig. 6B). However, the level 
of protection from Vpr-induced damage was lower for the petite mutant than for wild type yeast, 
with all treatments. Collectively, these results suggested that the Vpr-induced growth arrest might be 
caused as a consequence of intracellular depletion of ATP stores. 
4. Discussion 
Using S. cerevisiae, we here demonstrate that the cellular damage induced by de novo synthesized 
Vpr is blocked by extracellular GSH, NAC and ATP. Our results are consistent with previous 
observations showing that GSH levels in erythrocytes and T cells decreased as HIV disease 
progressed in a patient, and a significant restoration of both T cell GSH and total GSH in the whole 
blood occurred after oral administration of NAC (De Rosa et al., 2000). An indirect functioning of 
DHA might explain its modest protection against Vpr-induced cellular damage in comparison with 
ATP, GSH and NAC. DHA stimulates the pentose phosphate pathway and intracellular glutathione 
levels (Kim et al., 2005; Puskas et al., 2000), and Vpr might dampen the glycolytic pathway 
(Ferrucci et al., 2013). While exogenous DHA may have stimulated energetic metabolism of Vpr-
treated yeast, a toxic side effect was demonstrated at the highest concentration assayed (7.5 mM). 
Glutathione is the most abundant low molecular weight thiol involved in antioxidant defense in 
eukaryotic cells. In eukaryotic cells, the greatest concentration of GSH is found in mitochondria and 
subsequently in the cytosol, nuclei, cell walls and vacuoles (Zechmann et al., 2011). In minimal 
media, yeast need to synthesize GSH in order to survive and grow (Baudouin-Cornu et al., 2012). 
Thus, growth stimulation caused by exogenous GSSG might be explained by its exploitation as a 
sulfur/nitrogen source after degradation. Another fact worth mentioning is that glutathione 
concentrates in the nucleus, where it promotes cell cycle progression via an ATP-dependent 
mechanism. In yeast, the half-life of GSH is approximately 90 min and two molecules of ATP are 
consumed during the synthesis of one GSH molecule from cysteine (Mehdi and Penninckx, 1997). 
Thus, the potential inhibition of ATP synthesis in the mitochondrion by Vpr should be reflected by 
an intracellular depletion of GSH. In contrast, exogenous addition of ATP would benefit GSH 
synthesis and transport to the nucleus, and subsequently yeast growth. Additionally, GSSG is stored 
in the vacuole for further catabolism. Therefore, replenishment of the vacuole with exogenously-
supplied GSSG may explain the growth stimulation of Vpr-yeast by oxidized glutathione. Here we 
observed that autophagic bodies accumulated in the vacuole of untreated wild type cells but not in 
GSH-treated cells. The recovery of vacuole functioning might be related with increased levels of 
H
+




Mitochondria are the major sites of metabolic energy production in eukaryotic cells via the process 
of oxidative phosphorylation. COX subunits are significantly induced during respiration and are 
necessary for assembly of complex IV of the electron transport chain (ETC) (Ohlmeier et al., 2004). 
Conversely, unassembled subunits of the enzymatic complex undergo posttranslational degradation. 
Of note is the high recovery of Cox2p and Cox4p levels by treatment with ATP, GSH or NAC in 
Vpr-expressing cells. COX is the terminal enzyme of the ETC and reduces molecular oxygen to 
water to generate ATP by the action of ATP synthase. The variations in the levels of subunits 2 and 4 
were much higher in Vpr-yeast than in control yeast, suggesting that Vpr protein directly affects ATP 
production in mitochondria. Similarly, diminished levels of vacuolar ATPase by Vpr and high 
restoration of protein levels in treated cells suggest a Vpr-induced depletion of cytosolic ATP. 
During exponential growth, cells can change nuclear gene expression by using the mitochondrial 
retrograde response. Thus, low ATP levels may activate the mitochondrial retrograde signaling 
pathway (Liu and Butow, 2006). The inability of Vpr-expressing yeast to stimulate expression of the 
nuclear-encoded Cox4p suggests that mitochondrial signaling is impaired by Vpr protein. 
Furthermore, as a response to Vpr expression, steady-state levels of the GSH channel, Por1, might 
not be sufficient to ensure GSH ingress into the intermembrane mitochondria space from the cytosol, 
where it is synthesized (Kojer et al., 2012). The levels of GSH are equivalent in normal and petite 
yeasts (Grant et al., 1997). It is important to consider that the oxidant sensitivity of slow growing 
petite mutants has been related to their depleted ATP levels rather than with any lack of antioxidative 
stress response. Indeed, disruption of the respiratory ETC results in sensitivity to oxidative stress. 
This sensitivity may explain the growth stimulation of mitochondrial mutants observed with 
antioxidant treatments.  
Mechanisms mediating the pleiotropic functions of Vpr have been investigated for many years, but 
how this multitasking protein interacts with cells remains enigmatic (Guenzel et al., 2014; 
Muthumani et al., 2005). Heterologous overexpression in S. cerevisiae is a useful model to analyze 
the influence of viral proteins on cellular functioning (Alves-Rodrigues et al., 2006). Previous results 
have shown that this eukaryotic model is susceptible to the cell damage induced by the HIV-1 Vpr 
protein (Macreadie et al., 1995). Here we show that the S. cerevisiae model permits the analysis of 
Vpr interactions with the oxidative response and energy metabolism of eukaryotic cells and, 
consequently, should facilitate the search for Vpr targeted inhibitors. 
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